The major cause of COVID-19 patient death is inflammation-related complication, and ORF3a is the major inflammation inducer. Targeting ORF3a can be a effective way to reduce COVID-19-related patient death.

What it does

We are screening drugs that reduce ORF3a protein levels, leading to decreased inflammation.

How I built it

Construct ORF3a-GFP-reporter lines and perform drug screening.

Challenges I ran into

Scheduling and coordinate with different people during the lockdown.

Accomplishments that I'm proud of

We have the platform established for the large-scale drug screening.

What I learned

Together, we will win the battle with COVID-19!

What's next for Targeting ORF-3a mediated inflammation in COVID-19 patients

Screen and optimize the lead compound.

Share this project: